Inactive Instrument
Norda ASA Share Price Oslo Bors
Stocks
NORD
NO0010285190
Biotechnology & Medical Research
| Market Cap | 51Cr 5.3Cr 4.65Cr 4.3Cr 3.95Cr 7.45Cr 511.23Cr 7.57Cr 51Cr 20Cr 250.14Cr 20Cr 19Cr 861.81Cr | P/E 2023 * |
-
| P/E 2024 | 3.26x |
|---|---|---|---|---|---|
| Enterprise Value | 26Cr 2.73Cr 2.39Cr 2.21Cr 2.03Cr 3.84Cr 263.35Cr 3.9Cr 26Cr 10Cr 128.86Cr 10Cr 10Cr 443.95Cr | EV / Sales 2023 |
-1.24x | EV / Sales 2024 | 0.4x |
| Free-Float |
6.26% | Yield 2023 * |
-
| Yield 2024 | 32.5% |
| 09/04 | Exercise of Warrants by primary insiders | AQ |
| 10/25/10 | Mandatory Notification of Trade | AQ |
| 04/25/04 | Ocean Sun: Mandatory notification of trade | AQ |
| 27/25/27 | Nykode Therapeutics - Mandatory Notification of Trade by Closely Associated Party of a Primary Insider | AQ |
| 03/25/03 | Notification of trade | AQ |
| 1 day | +3.37% |
| Manager | Title | Age | Since |
|---|---|---|---|
Frode Westvold
CEO | Chief Executive Officer | - | 08/04/2013 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 54 | 31/01/2014 | |
| Director/Board Member | 68 | 20/06/2013 | |
| Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.37% | -6.12% | - | - | 4.58Cr | ||
| -0.49% | -4.01% | -0.84% | +2.28% | 4.87TCr | ||
| -3.10% | -1.94% | +370.99% | +572.60% | 3.84TCr | ||
| -0.46% | +2.18% | +5.44% | +61.01% | 3.45TCr | ||
| -1.14% | -1.76% | +26.94% | -9.93% | 3.4TCr | ||
| -1.82% | -1.43% | +0.52% | +31.85% | 2.68TCr | ||
| -3.54% | -5.08% | - | - | 1.56TCr | ||
| -1.82% | -0.43% | +69.28% | +113.82% | 1.51TCr | ||
| +1.17% | +2.30% | +15.87% | +18.26% | 1.42TCr | ||
| -2.25% | +0.05% | +15.77% | -32.83% | 1.27TCr | ||
| Average | -1.01% | -1.12% | +63.00% | +94.63% | 2.67TCr | |
| Weighted average by Cap. | -1.42% | -1.44% | +74.77% | +116.99% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 8.69Cr 89.8L 78.71L 72.75L 66.91L 1.26Cr 87Cr 1.28Cr 8.7Cr 3.41Cr 42Cr 3.37Cr 3.3Cr 145.98Cr | 37Cr 3.84Cr 3.37Cr 3.11Cr 2.86Cr 5.4Cr 370.45Cr 5.49Cr 37Cr 15Cr 181.26Cr 14Cr 14Cr 624.48Cr |
| Net income | 3.12Cr 32.2L 28.23L 26.09L 24L 45.28L 31Cr 46L 3.12Cr 1.22Cr 15Cr 1.21Cr 1.18Cr 52Cr | 13Cr 1.3Cr 1.14Cr 1.05Cr 96.95L 1.83Cr 125.47Cr 1.86Cr 13Cr 4.94Cr 61Cr 4.89Cr 4.78Cr 211.51Cr |
| Net Debt | -31Cr -3.22Cr -2.82Cr -2.61Cr -2.4Cr -4.52Cr -310.07Cr -4.59Cr -31Cr -12Cr -151.71Cr -12Cr -12Cr -522.7Cr | -25Cr -2.57Cr -2.25Cr -2.08Cr -1.92Cr -3.61Cr -247.88Cr -3.67Cr -25Cr -9.76Cr -121.28Cr -9.65Cr -9.44Cr -417.86Cr |
Employees
-
















